These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11350895)

  • 21. Soluble Fas (sFas) and soluble Fas ligand (sFas-L) balance in laryngeal carcinoma before and after surgical treatment.
    Pignataro L; Arisi E; Sambataro G; Corsi MM
    J Surg Oncol; 2003 Jun; 83(2):112-5. PubMed ID: 12772205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment.
    Tinazzi E; Puccetti A; Gerli R; Rigo A; Migliorini P; Simeoni S; Beri R; Dolcino M; Martinelli N; Corrocher R; Lunardi C
    Int Immunol; 2009 Mar; 21(3):237-43. PubMed ID: 19181929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An unexpected inverse correlation between soluble epidermal growth factor receptor and interleukin-6 in metastatic malignant melanoma patients.
    Mouawad R; Soubrane C; Rixe O; Khayat D; Spano JP
    Melanoma Res; 2006 Aug; 16(4):335-40. PubMed ID: 16845329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Soluble Fas (CD95) is a prognostic factor in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous stem cell transplantation.
    Bewick M; Conlon M; Parissenti AM; Lee H; Zhang L; Glück S; Lafrenie RM
    J Hematother Stem Cell Res; 2001 Dec; 10(6):759-68. PubMed ID: 11798502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage fluid in lung cancer patients.
    Erdoğan B; Uzaslan E; Budak F; Karadağ M; Ediger D; Oral B; Göral G; Ege E; Gözü O
    Tuberk Toraks; 2005; 53(2):127-31. PubMed ID: 16100648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Soluble Fas and soluble Fas L levels in patients with acute pancreatitis.
    Endo S; Inoue Y; Fujino Y; Yamada Y; Sato N; Wakabayashi G; Sakamoto T; Ishikura H; Tanaka T; Inada K; Sato S
    Res Commun Mol Pathol Pharmacol; 2000; 108(3-4):179-86. PubMed ID: 11913710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum soluble Fas levels in patients with autoimmune rheumatic diseases.
    Sahin M; Aydintug O; Tunc SE; Tutkak H; Naziroğlu M
    Clin Biochem; 2007 Jan; 40(1-2):6-10. PubMed ID: 17056024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of Fas ligand and sFas ligand in human gastric adenocarcinomas.
    Lim SC
    Oncol Rep; 2002; 9(1):103-7. PubMed ID: 11748465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients.
    Kimura M; Tomita Y; Imai T; Saito T; Katagiri A; Tanikawa T; Takeda M; Takahashi K
    Br J Cancer; 1999 Jul; 80(10):1648-51. PubMed ID: 10408413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Importance of FAS-1377, FAS-670, and FASL-844 polymorphisms in tumor onset, progression, and pigment phenotypes of Swedish patients with melanoma: a case-control analysis.
    Zhang H; Sun XF; Synnerstad I; Rosdahl I
    Cancer J; 2007; 13(4):233-7. PubMed ID: 17762757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of apoptosis markers in advanced heart failure patients.
    Niessner A; Hohensinner PJ; Rychli K; Neuhold S; Zorn G; Richter B; Hülsmann M; Berger R; Mörtl D; Huber K; Wojta J; Pacher R
    Eur Heart J; 2009 Apr; 30(7):789-96. PubMed ID: 19196721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum and follicular fluid levels of soluble Fas, soluble Fas ligand and apoptosis of luteinized granulosa cells in PCOS patients undergoing IVF.
    Onalan G; Selam B; Baran Y; Cincik M; Onalan R; Gündüz U; Ural AU; Pabuccu R
    Hum Reprod; 2005 Sep; 20(9):2391-5. PubMed ID: 15932917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased levels of soluble Fas in serum from diabetic patients with neuropathy.
    Guillot R; Bringuier AF; Porokhov B; Guillausseau PJ; Feldmann G
    Diabetes Metab; 2001 Jun; 27(3):315-21. PubMed ID: 11431596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of sFas indicates apoptosis in human herpes simplex encephalitis.
    Sabri F; Granath F; Hjalmarsson A; Aurelius E; Sköldenberg B
    J Neuroimmunol; 2006 Feb; 171(1-2):171-6. PubMed ID: 16325272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
    Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF
    Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Soluble Fas and soluble Fas ligand levels in patients with acute hepatic failure.
    Nakae H; Narita K; Endo S
    J Crit Care; 2001 Jun; 16(2):59-63. PubMed ID: 11481600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
    Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
    J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance and diagnostic value of protein S-100 and tyrosinase in patients with malignant melanoma.
    Andrés R; Mayordomo JI; Visus C; Isla D; Godino J; Escudero P; Saenz A; Ortega E; Lastra R; Lambea J; Aguirre E; Elosegui L; Marcos I; Ruiz-Echarri M; Millastre E; Sáez-Gutierrez B; Asin L; Vidal MJ; Ferrer A; Giner A; Larrad L; Carapeto FJ; Tres A
    Am J Clin Oncol; 2008 Aug; 31(4):335-9. PubMed ID: 18845991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome.
    Mouawad R; Spano JP; Comperat E; Capron F; Khayat D
    Eur J Cancer; 2009 May; 45(8):1407-14. PubMed ID: 19157860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical importance of circulating and cellular expression levels of Fas and Fas ligand in pediatric patients with lymphoproliferative malignancies.
    Hazar V; Berber Z; Pestereli E; Coskun M; Yesilipek A; Karpuzoglu G; Yegin O
    Pediatr Hematol Oncol; 2005; 22(3):247-56. PubMed ID: 16020109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.